Zurcher Kantonalbank (Zurich Cantonalbank) Atea Pharmaceuticals, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

  • $32.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 01, 2023
BUY
$4.35 - $6.17 $8,112 - $11,507
1,865 Added 18.48%
11,955 $57,000
Q2 2022

Aug 09, 2022
BUY
$5.33 - $8.18 $35,289 - $54,159
6,621 Added 190.86%
10,090 $72,000
Q4 2021

Feb 01, 2022
BUY
$7.67 - $44.59 $5,215 - $30,321
680 Added 24.38%
3,469 $31,000
Q3 2021

Nov 15, 2021
BUY
$21.33 - $35.06 $57,441 - $94,416
2,693 Added 2805.21%
2,789 $98,000
Q2 2021

Jul 30, 2021
BUY
$19.22 - $59.08 $1,845 - $5,671
96 New
96 $2,000

Others Institutions Holding AVIR

# of Institutions
112
Shares Held
52.4M
Call Options Held
900
Put Options Held
126K
View Full List

About Atea Pharmaceuticals, Inc.

AVIR Quotes by TradingView
  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $281M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email